LISA HARVEY: Open Payments
NPI 1962409334 · HOT SPRINGS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,800 in 125 payments from 18 companies in 2025. Trend: 2023 $1,542 · 2024 $1,251 · 2025 $1,800
Food & beverage: $1,800
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $351 |
| AstraZeneca Pharmaceuticals LP | 14 | $255 |
| Novo Nordisk Inc | 14 | $199 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $178 |
| Lilly USA, LLC | 11 | $147 |
| Abbott Laboratories | 5 | $113 |
| Aimmune Therapeutics, Inc. | 5 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $83 |
| Amgen Inc. | 4 | $55 |
Products named: UBRELVY, CAPLYTA, REXULTI, AIRSUPRA, MOUNJARO, ZENPEP, QULIPTA, BREZTRI.
Industry payments across AR — which companies pay providers there.
